Loading stock data…
Oramed Pharmaceuticals Inc (ORMP)
$4.81+0.17 (+3.66%)
After Hours$4.81+0.00 (+0.01%)· Last close Jun 30
Oramed Pharmaceuticals Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Oramed Pharmaceuticals Inc. in the Healthcare sector is trading at $4.81 with a market capitalization of $158M. Wall Street consensus targets $6.25 (1 analysts), implying a +29.9% move over the next 12 months. The stock is currently near its 52-week high of $5.19, remaining 51.7% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +29.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0↓ | $2.00M |
| Gross Profit | $0 | $0 | $0 | $0↓ | $13,000 |
| Operating Income | -$3.66M↑ | -$5.67M↓ | -$2.43M↑ | -$2.49M↑ | -$4.50M |
| Net Income | $38.31M↑ | $10.01M↓ | $48.40M↑ | $13.29M↑ | -$7.64M |
Peer Comparison
JNJUNHPFE
Fundamentals
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$157.97M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
46.17%
Volume
Today's trading volume
368,716
Recent News
June 2026 Penny Stocks To Watch For Potential Growth
Over the last 7 days, the market has remained flat, but it is up 24% over the past year, with earnings expected to grow by 19% per annum over the next few years. For investors willing to explore beyond well-known stocks, penny stocks — often representing smaller or newer companies — can present intriguing opportunities. Despite being a somewhat outdated term, penny stocks remain a relevant investment area for those seeking potential growth and financial resilience in lesser-known companies.
Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny Stocks
The market has climbed 1.5% in the last 7 days and is up 26% over the last 12 months, with earnings forecast to grow by 17% annually. While the term 'penny stock' might seem outdated, these investments still offer potential value by focusing on smaller or newer companies with strong financials. In this article, we explore three penny stocks that demonstrate financial strength and could present opportunities for investors seeking hidden value in quality companies.
Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors
The market has shown impressive growth, with a 4.2% increase over the last week and a 29% rise over the past year, while earnings are projected to grow by 16% annually. Although the term 'penny stock' may seem outdated, it still represents an area of investment that can uncover significant opportunities in smaller or newer companies. By focusing on those with strong financials and clear growth potential, investors can find hidden value in quality penny stocks that offer both stability and...
Oramed: Q4 Earnings Snapshot
NEW YORK (AP) — Oramed Pharmaceuticals Inc. ORMP) on Thursday reported profit of $10 million in its fourth quarter. The New York-based company said it had net income of 24 cents per share.
CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround
CarMax runs a nationwide network of used car stores and digital channels, offering multi-channel sales and financing to U.S. consumers.